This study did not find an association between methylation of ACE2 promoter and the presence of post-COVID-19 fatigue, dyspnea, cognitive or gastrointestinal problems up to one and a half years after an acute SARS-CoV-2 infection in a cohort of COVID-19 survivors who required hospitalization during the first wave of the outbreak. Here, ACE2 is linked to COVID-19.